$50 Million
Joint Bookrunner
Initial Public Offering
February 2016
$410 Million
Exclusive Financial Advisor
Sale of Hemostasis Portfolio to Mallinckrodt plc
February 2016
$86 Million
Joint Bookrunner
Follow-On
January 2016
Undisclosed
Exclusive Financial Advisor
Sale to Consonance Capital Partners
January 2016
$120 Million
Joint Bookrunner
Follow-On
January 2016
$150 Million
Joint Bookrunner
Follow-On
January 2016
$275 Million
Exclusive Financial Advisor
Sale to NeoGenomics Laboratories
December 2015
$34 Million
Co-Manager
Follow-On
December 2015
$50 Million
Exclusive Placement Agent
Private Placement
December 2015
CHF 60 Million
Exclusive Financial Advisor
Private Placement
November 2015
$23 Million
Exclusive Placement Agent
Private Placement
November 2015
$45 Million
Exclusive Financial Advisor
Sale to Abcam plc
November 2015